Thomsen Karina G, Terp Mikkel G, Lund Rikke R, Søkilde Rolf, Elias Daniel, Bak Martin, Litman Thomas, Beck Hans C, Lyng Maria B, Ditzel Henrik J
Institute of Molecular Medicine, Department of Cancer and Inflammation Research, University of Southern Denmark, Odense, Denmark.
Department of Biomarker Discovery, Exiqon A/S, Vedbaek, Denmark.
Oncotarget. 2015 Oct 6;6(30):29224-39. doi: 10.18632/oncotarget.4942.
To gain insight into miRNA regulation in metastasis formation, we used a metastasis cell line model that allows investigation of extravasation and colonization of circulating cancer cells to lungs in mice. Using global miRNA profiling, 28 miRNAs were found to exhibit significantly altered expression between isogenic metastasizing and non-metastasizing cancer cells, with miR-155 being the most differentially expressed. Highly metastatic mesenchymal-like CL16 cancer cells showed very low miR-155 expression, and miR-155 overexpression in these cells lead to significantly decreased tumor burden in lungs when injected intravenously in immunodeficient mice. Our experiments addressing the underlying mechanism of the altered tumor burden revealed that miR-155-overexpressing CL16 cells were less invasive than CL16 control cells in vitro, while miR-155 overexpression had no effect on cancer cell proliferation or apoptosis in established lung tumors. To identify proteins regulated by miR-155 and thus delineate its function in our cell model, we compared the proteome of xenograft tumors derived from miR-155-overexpressing CL16 cells and CL16 control cells using mass spectrometry-based proteomics. >4,000 proteins were identified, of which 92 were consistently differentially expressed. Network analysis revealed that the altered proteins were associated with cellular functions such as movement, growth and survival as well as cell-to-cell signaling and interaction. Downregulation of the three metastasis-associated proteins ALDH1A1, PIR and PDCD4 in miR-155-overexpressing tumors was validated by immunohistochemistry. Our results demonstrate that miR-155 inhibits the ability of cancer cells to extravasate and/or colonize at distant organs and brings additional insight into the complexity of miR-155 regulation in metastatic seeding.
为深入了解微小RNA(miRNA)在转移形成中的调控作用,我们使用了一种转移细胞系模型,该模型可用于研究循环癌细胞在小鼠肺部的外渗和定植情况。通过全局miRNA谱分析,发现28种miRNA在同基因转移和非转移癌细胞之间表现出显著改变的表达,其中miR-155的表达差异最为明显。高转移性间充质样CL16癌细胞显示出非常低的miR-155表达,在免疫缺陷小鼠中静脉注射这些细胞时,miR-155在这些细胞中的过表达导致肺部肿瘤负荷显著降低。我们针对肿瘤负荷改变的潜在机制进行的实验表明,在体外,过表达miR-155的CL16细胞比CL16对照细胞的侵袭性更低,而miR-155过表达对已形成的肺部肿瘤中的癌细胞增殖或凋亡没有影响。为了鉴定受miR-155调控的蛋白质,从而在我们的细胞模型中描绘其功能,我们使用基于质谱的蛋白质组学比较了源自过表达miR-155的CL16细胞和CL16对照细胞的异种移植肿瘤的蛋白质组。鉴定出了>4000种蛋白质,其中92种始终存在差异表达。网络分析表明,这些改变的蛋白质与细胞运动、生长和存活以及细胞间信号传导和相互作用等细胞功能相关。通过免疫组织化学验证了过表达miR-155的肿瘤中三种转移相关蛋白ALDH1A1、PIR和PDCD4的下调。我们的结果表明,miR-155抑制癌细胞在远处器官外渗和/或定植的能力,并为转移播种中miR-155调控的复杂性带来了更多见解。